PE20130324A1 - Proteinas de fusion que comprenden un antigeno prame (dage) - Google Patents
Proteinas de fusion que comprenden un antigeno prame (dage)Info
- Publication number
- PE20130324A1 PE20130324A1 PE2012001372A PE2012001372A PE20130324A1 PE 20130324 A1 PE20130324 A1 PE 20130324A1 PE 2012001372 A PE2012001372 A PE 2012001372A PE 2012001372 A PE2012001372 A PE 2012001372A PE 20130324 A1 PE20130324 A1 PE 20130324A1
- Authority
- PE
- Peru
- Prior art keywords
- fusion protein
- amino acids
- protein
- dage
- fusion proteins
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 5
- 102000036673 PRAME Human genes 0.000 title abstract 2
- 108060006580 PRAME Proteins 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 102000037865 fusion proteins Human genes 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 102000019034 Chemokines Human genes 0.000 abstract 1
- 108010012236 Chemokines Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 abstract 1
- 102100039564 Leukosialin Human genes 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001189—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UNA PROTEINA DE FUSION QUE COMPRENDE: (a) UN PRAME O UN FRAGMENTO INMUNOLOGICO DEL MISMO QUE CONSTA DE UNO O MAS DE LOS EPITOPES SIGUIENTES: (i) VLDGLDVLL; (ii) SLYSFPEPEA ; ENTRE OTROS; (b) UNA PROTEINA PAREJA DE FUSION HETEROLOGA DERIVADA DE PROTEINA D QUE ESTA CONSTITUIDA POR LOS AMINOACIDOS 20 A 127 DE LA PROTEINA D Y LOS AMINOACIDOS LYS-21 Y LEU-22 ESTAN SUSTITUIDOS CON LOS AMINOACIDOS ASP-21 Y PRO-22; (C) UNA O MAS SECUENCIAS DE ENGARCE ENTRE LA PROTEINA FUSION Y EL ANTIGENO TUMORAL. REFERIDA ADEMAS A UN PROCEDIMIENTO Y A UNA VACUNA QUE CONTIENE UN COADYUVANTE TALES COMO 3D-MPL, QS21 Y/O OLIGONUCLEOTIDO CpG, Y/O UNA CITOQUINA O QUIMIOQUINA INMUNOESTIMULADORA. DICHA COMPOSICION QUE CONTIENE LA PROTEINA DE FUSION ES UTIL EN EL TRATAMIENTO DEL CANCER.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0700760A GB0700760D0 (en) | 2007-01-15 | 2007-01-15 | Vaccine |
GB0701262A GB0701262D0 (en) | 2007-01-23 | 2007-01-23 | Vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20130324A1 true PE20130324A1 (es) | 2013-03-05 |
Family
ID=39300029
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008000124A PE20081686A1 (es) | 2007-01-15 | 2008-01-11 | Proteinas de fusion que comprenden un antigeno prame (dage) |
PE2012001372A PE20130324A1 (es) | 2007-01-15 | 2008-01-11 | Proteinas de fusion que comprenden un antigeno prame (dage) |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008000124A PE20081686A1 (es) | 2007-01-15 | 2008-01-11 | Proteinas de fusion que comprenden un antigeno prame (dage) |
Country Status (32)
Country | Link |
---|---|
US (1) | US20080187535A1 (es) |
EP (1) | EP2114993B1 (es) |
JP (1) | JP5391080B2 (es) |
KR (1) | KR20090101313A (es) |
CN (1) | CN101668770B (es) |
AR (1) | AR064862A1 (es) |
AU (1) | AU2008207025B2 (es) |
BR (1) | BRPI0806463A2 (es) |
CA (1) | CA2674552A1 (es) |
CL (1) | CL2008000104A1 (es) |
CO (1) | CO6210757A2 (es) |
CR (1) | CR10971A (es) |
CY (1) | CY1113760T1 (es) |
DK (1) | DK2114993T3 (es) |
DO (1) | DOP2009000167A (es) |
EA (1) | EA016326B1 (es) |
ES (1) | ES2393812T3 (es) |
HK (1) | HK1138853A1 (es) |
HR (1) | HRP20120828T1 (es) |
IL (1) | IL199663A0 (es) |
JO (1) | JO2840B1 (es) |
MA (1) | MA31093B1 (es) |
MX (1) | MX2009007571A (es) |
MY (1) | MY153679A (es) |
NZ (1) | NZ578285A (es) |
PE (2) | PE20081686A1 (es) |
PL (1) | PL2114993T3 (es) |
PT (1) | PT2114993E (es) |
SI (1) | SI2114993T1 (es) |
TW (1) | TWI434697B (es) |
WO (1) | WO2008087102A1 (es) |
ZA (1) | ZA200904923B (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2118128B1 (en) * | 2007-01-15 | 2012-11-07 | GlaxoSmithKline Biologicals SA | Fusion proteins comprising the tumor rejection antigens ny-eso-1 and lage-1 |
JP2012520663A (ja) | 2009-03-17 | 2012-09-10 | エムディーエックスヘルス エスエー | 遺伝子発現の改良された検出 |
EP2438173A4 (en) * | 2009-06-05 | 2012-10-31 | Univ Ohio State Res Found | BIOMATERIALS, COMPOSITIONS AND METHODS |
GB0910046D0 (en) | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
GB201008682D0 (en) * | 2010-05-25 | 2010-07-07 | Vib Vzw | Epitope tag for affinity based applications |
GB201101331D0 (en) * | 2011-01-26 | 2011-03-09 | Glaxosmithkline Biolog Sa | Compositions and uses |
KR20140049569A (ko) | 2011-07-22 | 2014-04-25 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Prame 정제 |
GB201114919D0 (en) * | 2011-08-30 | 2011-10-12 | Glaxosmithkline Biolog Sa | Method |
GB201116248D0 (en) | 2011-09-20 | 2011-11-02 | Glaxosmithkline Biolog Sa | Liposome production using isopropanol |
RU2590701C2 (ru) * | 2013-04-29 | 2016-07-10 | Общество с ограниченной ответственностью "ГеноТехнология" | Антигенная композиция и ее терапевтическое применение для профилактики и лечения онкологических заболеваний, рекомбинантная плазмидная днк, обеспечивающая синтез гибридного белка, а также способ получения белка |
US20160367651A1 (en) | 2013-10-01 | 2016-12-22 | Mie University | T cell inducing vaccine containing an interepitope sequence that promotes antigen presentation |
CN105254767A (zh) * | 2015-11-17 | 2016-01-20 | 重庆科润生物医药研发有限公司 | 一种Protein D与HER2融合蛋白及其制备方法和应用 |
NZ753307A (en) | 2016-11-30 | 2023-10-27 | Advaxis Inc | Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof |
CN108264550B (zh) * | 2017-01-04 | 2021-04-23 | 香雪生命科学技术(广东)有限公司 | 一种识别源自于prame抗原短肽的tcr |
CN108948184B (zh) * | 2017-05-22 | 2021-04-23 | 香雪生命科学技术(广东)有限公司 | 一种识别衍生自prame抗原短肽的t细胞受体 |
CN109400697B (zh) * | 2017-08-17 | 2021-04-23 | 香雪生命科学技术(广东)有限公司 | 一种识别prame抗原短肽的tcr及其相关组合物 |
WO2019061297A1 (zh) * | 2017-09-29 | 2019-04-04 | 苏州工业园区唯可达生物科技有限公司 | 一种cd4辅助性t细胞表位融合肽及其疫苗 |
US20210177955A1 (en) * | 2017-11-08 | 2021-06-17 | Advaxis, Inc. | Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof |
CN109879957B (zh) * | 2017-12-06 | 2022-03-18 | 香雪生命科学技术(广东)有限公司 | 针对prame的高亲和力t细胞受体 |
US20230190902A1 (en) * | 2020-05-29 | 2023-06-22 | Children's National Medical Center | Identification of hla-restricted prame peptide epitopes, prame-specific t cells suitable for "off-the-shelf" treatment of cancer expressing prame |
JP2024518378A (ja) | 2021-05-05 | 2024-05-01 | イマティクス バイオテクノロジーズ ゲーエムベーハー | Prameに特異的に結合する抗原結合タンパク質 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE466259B (sv) * | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
CA2156718A1 (en) * | 1993-12-23 | 1995-06-29 | Bruno Gander | Immunological response potentiation process |
US5830753A (en) | 1994-09-30 | 1998-11-03 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof. |
GB9717953D0 (en) * | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
SI1659179T1 (sl) * | 1998-02-05 | 2011-10-28 | Glaxosmithkline Biolog Sa | S tumorjem povezani antigenski derivati iz MAGE druĹľine in zaporedja nukleinskih kislin, ki jih kodirajo, uporabni za pripravo fuzijskih proteinov in sestavkov za cepljenje |
EP1156825A2 (en) * | 1999-02-25 | 2001-11-28 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Immunogens comprising a peptide and a carrier derived from h.influenzae protein d |
WO2001000232A2 (en) * | 1999-06-29 | 2001-01-04 | Smithkline Beecham Biologicals S.A. | Use of cpg as an adjuvant for hiv vaccine |
CN1367875A (zh) * | 1999-07-08 | 2002-09-04 | 斯特思吉生物技术公司 | 活体外th1一样反应的诱导方法 |
-
2008
- 2008-01-11 CN CN2008800078884A patent/CN101668770B/zh not_active Expired - Fee Related
- 2008-01-11 JP JP2009545186A patent/JP5391080B2/ja not_active Expired - Fee Related
- 2008-01-11 TW TW097101177A patent/TWI434697B/zh not_active IP Right Cessation
- 2008-01-11 PE PE2008000124A patent/PE20081686A1/es not_active Application Discontinuation
- 2008-01-11 BR BRPI0806463-6A patent/BRPI0806463A2/pt not_active IP Right Cessation
- 2008-01-11 EA EA200900795A patent/EA016326B1/ru not_active IP Right Cessation
- 2008-01-11 PE PE2012001372A patent/PE20130324A1/es not_active Application Discontinuation
- 2008-01-11 MX MX2009007571A patent/MX2009007571A/es active IP Right Grant
- 2008-01-11 KR KR1020097017027A patent/KR20090101313A/ko not_active Application Discontinuation
- 2008-01-11 PL PL08701434T patent/PL2114993T3/pl unknown
- 2008-01-11 EP EP08701434A patent/EP2114993B1/en not_active Not-in-force
- 2008-01-11 PT PT08701434T patent/PT2114993E/pt unknown
- 2008-01-11 US US12/013,011 patent/US20080187535A1/en not_active Abandoned
- 2008-01-11 NZ NZ578285A patent/NZ578285A/en not_active IP Right Cessation
- 2008-01-11 WO PCT/EP2008/050290 patent/WO2008087102A1/en active Application Filing
- 2008-01-11 MY MYPI20092932A patent/MY153679A/en unknown
- 2008-01-11 AR ARP080100127A patent/AR064862A1/es active IP Right Grant
- 2008-01-11 DK DK08701434.6T patent/DK2114993T3/da active
- 2008-01-11 ES ES08701434T patent/ES2393812T3/es active Active
- 2008-01-11 CA CA002674552A patent/CA2674552A1/en not_active Abandoned
- 2008-01-11 AU AU2008207025A patent/AU2008207025B2/en not_active Ceased
- 2008-01-11 SI SI200830787T patent/SI2114993T1/sl unknown
- 2008-01-13 JO JO200815A patent/JO2840B1/en active
- 2008-01-14 CL CL200800104A patent/CL2008000104A1/es unknown
-
2009
- 2009-07-02 DO DO2009000167A patent/DOP2009000167A/es unknown
- 2009-07-02 IL IL199663A patent/IL199663A0/en unknown
- 2009-07-10 MA MA32087A patent/MA31093B1/fr unknown
- 2009-07-14 ZA ZA2009/04923A patent/ZA200904923B/en unknown
- 2009-07-15 CO CO09073705A patent/CO6210757A2/es not_active Application Discontinuation
- 2009-08-07 CR CR10971A patent/CR10971A/es unknown
-
2010
- 2010-05-03 HK HK10104329.2A patent/HK1138853A1/xx not_active IP Right Cessation
-
2012
- 2012-10-15 HR HRP20120828AT patent/HRP20120828T1/hr unknown
- 2012-11-09 CY CY20121101065T patent/CY1113760T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20130324A1 (es) | Proteinas de fusion que comprenden un antigeno prame (dage) | |
CY1121632T1 (el) | Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης | |
EA202192570A1 (ru) | Иммуногенные композиции и вакцины, содержащие пептиды и белки вируса африканской чумы свиней, и их применение | |
CL2024000411A1 (es) | Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos. | |
PE20190398A1 (es) | Anticuerpos nuevos que se unen especificamente a los epitopos del virus del zika y usos de los mismos | |
DOP2020000032A (es) | Proteínas de unión específicas y sus usos | |
GEP20217326B (en) | Constructs having a sirp-alpha domain or variant thereof | |
AR112604A1 (es) | Receptores de células t, e inmunoterapia usando los mismos | |
GT201000148A (es) | Anticuerpos antimesotelina y usos de los mismos | |
BR112019011450A2 (pt) | células naturais killer modificadas e uso das mesmas | |
PE20150605A1 (es) | Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico | |
CL2016001405A1 (es) | A peptide mixture | |
CR20180174A (es) | Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer | |
UY32812A (es) | Anticuerpos humanos de alta afinidad para angiopoyetina -2 humana. | |
EA201000207A1 (ru) | Новые иммуногенные эпитопы для иммунотерапии | |
CR20120026A (es) | Construcciones novedosas de proteína del virus de papiloma humano (hpv) y su uso en la prevención de la enfermedad por el hpv | |
EA201290131A1 (ru) | Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний | |
ES2337399T3 (es) | Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii. | |
CY1117214T1 (el) | Συνθεση για ελεγχομενη διεγερση των ωοθηκων | |
AR067666A1 (es) | Proteinas de union al antigeno del receptor de il-18 | |
UY32915A (es) | Proteínas de únión específicas y sus usos | |
BR112019012796A2 (pt) | proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas | |
CY1119737T1 (el) | Νεες συνθεσεις και μεθοδοι | |
EA202191175A1 (ru) | Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры | |
PE20081687A1 (es) | Proteina de fusion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |